Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb22841 · 1 trial · 23 indications
Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Arm 1: XmAb®22841 Monotherapy |
| Arm 2 | EXPERIMENTAL | Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®) |
| Name | Type | Description |
|---|---|---|
| XmAb®22841 | BIOLOGICAL | Monoclonal bispecific antibody |
| Pembrolizumab (Keytruda®) | BIOLOGICAL | FDA-approved humanized monoclonal antibody |
Inclusion Criteria: PART A (Dose Escalation Cohorts) 1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 2. All subjects must have adequate archival tumor,...
Top 20 of 52 competitors
XmAb22841 is an investigational monoclonal antibody being studied for the treatment of melanoma and other selected advanced solid tumors. It is being developed as a dual checkpoint inhibitor for oncology indications, including advanced or metastatic solid tumors. It is not an approved therapy and remains in clinical development.
XmAb22841 targets CTLA-4 and LAG-3, two immune checkpoint proteins. It is a bispecific monoclonal antibody that binds both targets simultaneously, which is why it is classified as a dual checkpoint inhibitor. This mechanism is intended to support antitumor immune activity in advanced solid tumors.
XmAb22841 is developed by Xencor, Inc., which trades on the Nasdaq under the ticker XNCR. Xencor is the sponsor of the clinical program evaluating the antibody in advanced solid tumors, including melanoma.
XmAb22841 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 program has been completed, and the drug remains a clinical-stage asset rather than an approved treatment.
XmAb22841 has been evaluated in one Phase 1 trial, NCT03849469, titled a study of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with selected advanced solid tumors. The trial enrolled 78 participants, was controlled, and has been completed. It was conducted in the United States.
Yes, XmAb22841 and XmAb®22841 refer to the same investigational monoclonal antibody developed by Xencor, Inc. The registered trademark symbol is simply part of the company's branding of the XmAb antibody platform, and both names identify the same CTLA-4 x LAG-3 dual checkpoint inhibitor.